EVALI stands for E-cigarette or Vaping product use Associated Lung Injury, a public health term describing severe pulmonary illness linked to vaping. Health agencies introduced this label to standardize case tracking, clinical guidance, and regulatory responses.
Below is a structured overview of how EVALI is defined, reported, and managed across clinical, regulatory, and market domains.
| Dimension | Detail | Key Indicator | Relevance |
|---|---|---|---|
| Full Meaning | E-cigarette or Vaping product use Associated Lung Injury | EVALI | Official CDC case definition for vaping-related lung injury |
| First Recognized | April 2019 | Cluster reports in Wisconsin and Illinois | Initial signal in national surveillance |
| Primary Cause | Vitamin E acetate in THC-containing vaping products | Strong epidemiologic link | Key chemical marker in patient samples |
| Typical Symptoms | Cough, shortness of breath, chest pain, fever, gastrointestinal signs | Biphasic respiratory illness | Overlap with pneumonia and ARDS |
| Diagnostic Criteria | CDC standardized case definition: respiratory symptoms + compatible imaging + no infectious etiology | Exclusion of alternative causes | Guides clinical reporting and research |
Clinical Recognition and Diagnosis of EVALI
Presentation and Imaging Findings
Patients with EVALI typically report subacute respiratory symptoms, often with gastrointestinal and constitutional features. Chest imaging commonly shows bilateral ground-glass opacities, reflecting acute lung injury.
Evaluation and Exclusion of Alternatives
Clinicians perform infectious workup, immunomodulatory assessment, and exposure history to differentiate EVALI from infections, autoimmune conditions, and other acute respiratory syndromes.
Regulatory Response and Product Controls
Market Restrictions and Flavor Bans
Health authorities moved swiftly to restrict flavored vaping products, limit sales of unregulated devices, and set product standards to reduce adulterated THC oils and vitamin E acetate contamination.
Tracking and Reporting Systems
National surveillance platforms and case-based reporting improved after EVALI recognition, enabling faster detection of emerging patterns and targeted product recalls.
Risk Factors and Exposure Patterns
Product Composition and Sources
Illicit THC-containing vaping products obtained from informal sources accounted for most EVALI cases, whereas nicotine-only products showed limited association.
Demographic and Behavioral Correlates
Young adults, current and recent vaping users, and those who modify products faced elevated risk, highlighting the importance of safe use messaging.
Public Health Implications and Ongoing Monitoring
- Standardized case definitions improved national surveillance and outbreak detection.
- Regulatory limits on flavored products reduced youth access and appeal.
- Clinician awareness and diagnostic criteria support timely identification and care.
- Continued monitoring informs long-term policies on vaping product composition and marketing.
FAQ
Reader questions
What exactly does EVALI stand for in medical terms?
EVALI stands for E-cigarette or Vaping product use Associated Lung Injury, the standardized term used by health authorities to describe severe lung disease linked to vaping.
Which vaping substances are most strongly linked to EVALI?
Vitamin E acetate found in illicit THC vaping oils is the primary chemical linked to EVALI cases, while nicotine-only products have shown limited association.
How quickly do symptoms of EVALI typically appear after vaping?
Symptoms often develop over days to weeks of exposure, with many patients reporting a gradual onset of cough, shortness of breath, and systemic features.
What steps can reduce the risk of EVALI for current vapers?
Avoid modifying devices, use regulated nicotine products from legitimate sources, and refrain from adding substances not intended by the manufacturer.